AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Assura PLC

Board/Management Information Jun 25, 2018

4924_rns_2018-06-25_7742bb3c-24c5-4ef3-a216-8adcea042675.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5086S

Assura PLC

25 June 2018

25 June 2018

Assura plc

Committee membership

Assura plc ("Assura" or the "Company"), the leading investor and developer of primary care properties, announces that upon Ed Smith's intended appointment as Chairman of the Company at the conclusion of the AGM on 10th July, he will be stepping down as member of the audit committee.

Jonathan Davies became a member of the audit, remuneration and nominations committees on his appointment as Non-Executive Director on 1 June 2018.

- Ends -

For more information, please contact:

Assura plc Tel: 01925 420660
Jonathan Murphy
Orla Ball
Edelman Tel: 0203 047 2546
John Kiely
Brett Jacobs
Rob Yates

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 31 March 2018, Assura's property portfolio was valued at £1,733 million.

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCFAMATMBMTBFP

Talk to a Data Expert

Have a question? We'll get back to you promptly.